Newborn Mice Vaccination with BCG.HIVA(222) plus MVA.HIVA Enhances HIV-1-Specific Immune Responses: Influence of Age and Immunization Routes

Dettagli Bibliografici
Autori principali:	Saubi, N, Im, E, Fernandez-Lloris, R, Gil, O, Cardona, P, Gatell, J, Hanke, T, Joseph, J
Natura:	Journal article
Pubblicazione:	2011

Newborn Mice Vaccination with BCG.HIVA222 + MVA.HIVA Enhances HIV-1-Specific Immune Responses: Influence of Age and Immunization Routes
di: Narcís Saubi, et al.
Pubblicazione: (2011-01-01)

Newborn mice vaccination with BCG.HIVA²²² + MVA.HIVA enhances HIV-1-specific immune responses: influence of age and immunization routes.
di: Saubi, N, et al.
Pubblicazione: (2011)

P17-17. Newborn mice vaccination with rBCG:HIVA + MVA:HIVA enhances HIV-1-specific immune responses. Influence of age and immunization routes
di: Hanke T, et al.
Pubblicazione: (2009-10-01)

Pre-clinical development of BCG.HIVA(CAT) strain, an antibiotic-free selection strain for HIV-TB pediatric vaccine
di: Saubi, N, et al.
Pubblicazione: (2012)

Pre-clinical development of BCG.HIVA(CAT), an antibiotic-free selection strain, for HIV-TB pediatric vaccine vectored by lysine auxotroph of BCG
di: Saubi, N, et al.
Pubblicazione: (2012)

Pre-clinical development of BCG.HIVA(CAT), an antibiotic-free selection strain, for HIV-TB pediatric vaccine vectored by lysine auxotroph of BCG.
di: Narcís Saubi, et al.
Pubblicazione: (2012-01-01)

Preclinical development of BCG.HIVA(2auxo.int), harboring an integrative expression vector, for a HIV-TB pediatric vaccine. Enhancement of stability and specific HIV-1 T-cell immunity
di: Mahant, A, et al.
Pubblicazione: (2017)

Preclinical development of BCG.HIVA2auxo.int, harboring an integrative expression vector, for a HIV-TB Pediatric vaccine. Enhancement of stability and specific HIV-1 T-cell immunity
di: Aakash Mahant, et al.
Pubblicazione: (2017-08-01)

pTHr.HIVA and MVA.HIVA vaccines (gag p24/p17) augment CD4+T cell responses in chronically infected HIV-1 patients on HAART
di: Ondondo, B, et al.
Pubblicazione: (2005)

Development of a DNA-MVA/HIVA vaccine for Kenya.
di: Hanke, T, et al.
Pubblicazione: (2002)

A phase I randomized clinical trial of candidate human immunodeficiency virus type 1 vaccine MVA.HIVA administered to Gambian infants
di: Afolabi, M, et al.
Pubblicazione: (2013)

A phase I randomized clinical trial of candidate human immunodeficiency virus type 1 vaccine MVA.HIVA administered to Gambian infants.
di: Muhammed O Afolabi, et al.
Pubblicazione: (2013-01-01)

Lessons from IAVI-006, a phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers.
di: Guimarães-Walker, A, et al.
Pubblicazione: (2008)

PedVacc001:Safety and Immunogenicity of a Candidate HIV-1 Vaccine, MVA.HIVA, Administered to Healthy Gambian Infants Born to HIV-1/2-Uninfected Mothers
di: Afolabi, M, et al.
Pubblicazione: (2011)

Safety and tolerability of recombinant modified vaccinia virus Ankara expressing an HIV-1 gag/multiepitope immunogen (MVA.HIVA) in HIV-1-infected persons receiving combination antiretroviral therapy.
di: Dorrell, L, et al.
Pubblicazione: (2007)

Lessons from IAVI-006, a Phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers (vol 26, pg 6671, 2008)
di: Guimaraes-Walker, A, et al.
Pubblicazione: (2011)

PedVacc 002: A phase I/II randomized clinical trial of MVA.HIVA vaccine administered to infants born to human immunodeficiency virus type 1-positive mothers in Nairobi
di: Njuguna, I, et al.
Pubblicazione: (2014)

PedVacc 002: a phase I/II randomized clinical trial of MVA.HIVA vaccine administered to infants born to human immunodeficiency virus type 1-positive mothers in Nairobi.
di: Njuguna, I, et al.
Pubblicazione: (2014)

Corrigendum to " Lessons from IAVI-006, a Phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers" [Vaccine 26 (2008) 6671-6677]
di: Guimarães-Walker, A, et al.
Pubblicazione: (2011)

Corrigendum to "Lessons from IAVI-006, a Phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers" [Vaccine 26 (2008) 6671-6677] (DOI:10.1016/j.vaccine.2008.09.016)
di: Guimarães-Walker, A, et al.
Pubblicazione: (2011)

Induction of long-lasting multi-specific CD8+ T cells by a four-component DNA-MVA/HIVA-RENTA candidate HIV-1 vaccine in rhesus macaques.
di: Im, E, et al.
Pubblicazione: (2006)

La Chaire de Dynamique Sociale et HIVA-KU Leuven : Une collaboration 'gagnant - gagnant'
di: Jan Van Ongevella
Pubblicazione: (2022-05-01)

Priming with Recombinant BCG Expressing HTI Enhances the Magnitude and Breadth of the T-Cell Immune Responses Elicited by MVA.HTI in BALB/c Mice
di: Narcís Saubi, et al.
Pubblicazione: (2020-11-01)

Lost bioscapes: Floristic and arthropod diversity coincident with 12th century Polynesian settlement, Nuku Hiva, Marquesas Islands.
di: Melinda S Allen, et al.
Pubblicazione: (2022-01-01)

Modified vaccinia Ankara expressing HIVA antigen stimulates HIV-1-specific CD8 T cells in ELISpot assays of HIV-1 exposed infants.
di: Slyker, J, et al.
Pubblicazione: (2005)

Tentative de discrimination des femelles adultes de simulies (Diptera : Simuliidae) à Nuku-Hiva (Archipel des Marquises, Polynésie Française )
di: Séchan Y., et al.
Pubblicazione: (2000-12-01)

Marine mammals of Easter Island (Rapa Nui) and Salas y Gómez Island (Motu Motiro Hiva), Chile: a review and new records
di: Rodrigo Hucke-Gaete, et al.
Pubblicazione: (2014-10-01)

Assessment of Ciguatera and Other Phycotoxin-Related Risks in Anaho Bay (Nuku Hiva Island, French Polynesia): Molecular, Toxicological, and Chemical Analyses of Passive Samplers
di: Mélanie Roué, et al.
Pubblicazione: (2020-05-01)

Toxicological Investigations on the Sea Urchin Tripneustes gratilla (Toxopneustidae, Echinoid) from Anaho Bay (Nuku Hiva, French Polynesia): Evidence for the Presence of Pacific Ciguatoxins
di: Hélène Taiana Darius, et al.
Pubblicazione: (2018-04-01)

Une appellation transnationale pour l’Océan Pacifique: Te moana nui a Kiwa (Nouvelle-Zélande) - Te moana nui a Hiva (Tahiti)
di: Bruno Saura
Pubblicazione: (2022-12-01)

Aspects du cycle d'agressivité de Simulium buissoni Roubaud, 1906 (Diptera : Simuliidae) à Nuku-Hiva, Archipel des Marquises (Polynésie Française)
di: Séchan Y., et al.
Pubblicazione: (2001-03-01)

Tectus niloticus (Tegulidae, Gastropod) as a Novel Vector of Ciguatera Poisoning: Detection of Pacific Ciguatoxins in Toxic Samples from Nuku Hiva Island (French Polynesia)
di: Hélène Taiana Darius, et al.
Pubblicazione: (2017-12-01)

First endemic arachnid from Isla Sala y Gómez (Motu Motiro Hiva), Chile: a new species of tube-dwelling spider (Araneae: Segestriidae)
di: André Marsola Giroti, et al.
Pubblicazione: (2020-10-01)

Tectus niloticus (Tegulidae, Gastropod) as a Novel Vector of Ciguatera Poisoning: Clinical Characterization and Follow-Up of a Mass Poisoning Event in Nuku Hiva Island (French Polynesia)
di: Clémence Mahana iti Gatti, et al.
Pubblicazione: (2018-02-01)

Répartition de Simulium buissoni Roubaud, 1906 et S . sechani Craig & Fossati, 1995 (Diptera: Simuliidae) à Nuku-Hiva et Eiao (Archipel des Marquises, Polynésie Française)
di: Séchan Y., et al.
Pubblicazione: (2000-12-01)

Engineering New E.coli-Mycobacterial Shuttle Vector for a Dual HIV-TB Pediatric Vaccine Vectored by Lysine Auxotroph of BCG
di: Saubi, N, et al.
Pubblicazione: (2013)

Evaluation of a human BCG challenge model to assess antimycobacterial immunity induced by BCG and a candidate TB vaccine, MVA85A, alone and in combination
di: Harris, S, et al.
Pubblicazione: (2013)

Evaluation of a human BCG challenge model to assess antimycobacterial immunity induced by BCG and a candidate tuberculosis vaccine, MVA85A, alone and in combination.
di: Harris, SA, et al.
Pubblicazione: (2014)

MVA as a vector for vaccines against HIV-1.
di: Im, E, et al.
Pubblicazione: (2004)

DEVELOPING A NEW TB VACCINE: BOOSTING BCG WITH MVA85A
di: Mcshane, H
Pubblicazione: (2008)

Newborn Mice Vaccination with BCG.HIVA(222) plus MVA.HIVA Enhances HIV-1-Specific Immune Responses: Influence of Age and Immunization Routes

Documenti analoghi

Documenti analoghi